Victory Capital Management’s Marker Therapeutics MRKR Stock Holding History

Victory Capital Management’s Portfolio MRKR Stock Details MRKR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-62,167	Closed	-$591K	–	2784
2021 Q4	$591K	Sell	62,167 -28,510	-31%	-$379K	﹤0.01%	2069
2021 Q3	$1.53M	Sell	90,677 -1,691	-2%	-$34.6K	﹤0.01%	1681
2021 Q2	$2.58M	Sell	92,368 -6,279	-6%	-$165K	﹤0.01%	1564
2021 Q1	$2.21M	Buy	+98,647	New	+$2.26M	﹤0.01%	1624
2020 Q2	–	Sell	-1,061	Closed	-$20K	–	2973
2020 Q1	$20K	Buy	+1,061	New	+$27K	﹤0.01%	3095
2019 Q4	–	Sell	-557	Closed	-$28K	–	3017
2019 Q3	$28K	Buy	+557	New	+$32.9K	﹤0.01%	2927

Other funds holding MRKR

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ACM

ACT Capital Management Wayne, Pennsylvania $153M AUM

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

AAM

AR Asset Management West Hollywood, California $517M AUM 18.31% 1-Year Est. Return

Victory Capital Management's MRKR Position: Q1 2022 in Review

Victory Capital Management sold out of Marker Therapeutics (MRKR) in Q1 2022, closing a stake of 62,167 shares — an estimated $591K sold.

Victory Capital Management first reported a position in MRKR in Q3 2019 and held it in 6 quarters. The position peaked at $2.58M in Q2 2021. 49 funds tracked by Wall St. Rank hold MRKR as of Q1 2022.

Victory Capital Management reported no remaining Marker Therapeutics position as of Q1 2022 after selling out during the quarter.
Victory Capital Management sold 62,167 Marker Therapeutics shares in Q1 2022, an estimated $591K.
Victory Capital Management first reported a position in Marker Therapeutics in Q3 2019 and held it in 6 quarters.
Victory Capital Management's Marker Therapeutics position peaked at $2.58M in Q2 2021.
49 funds tracked by Wall St. Rank held Marker Therapeutics as of Q1 2022.

Based on Victory Capital Management's 13F filing for Q1 2022, filed 4 May 2022.